Hereditary Angioedema Clinical Trials

7 recruiting

Hereditary Angioedema Trials at a Glance

12 actively recruiting trials for hereditary angioedema are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 3 with 5 trials, with the heaviest enrollment activity in St Louis, Barcelona, and Cincinnati. Lead sponsors running hereditary angioedema studies include ADARx Pharmaceuticals, Inc., CSL Behring, and Astria Therapeutics, Inc..

Browse hereditary angioedema trials by phase

Treatments under study

About Hereditary Angioedema Clinical Trials

Looking for clinical trials for Hereditary Angioedema? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hereditary Angioedema trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hereditary Angioedema clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

Donidalorsen Treatment in Children With Hereditary Angioedema

Hereditary Angioedema (HAE)
Ionis Pharmaceuticals, Inc.20 enrolled6 locationsNCT07298447
Recruiting
Phase 3

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled48 locationsNCT07428499
Recruiting
Phase 3

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Hereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled50 locationsNCT06960213
Recruiting
Phase 3

A Study of Navenibart in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.145 enrolled85 locationsNCT06842823
Recruiting
Phase 4

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Hereditary Angioedema
CSL Behring30 enrolled11 locationsNCT06806657
Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

Hereditary Angioedemas
CSL Behring200 enrolled18 locationsNCT07001280
Recruiting
Phase 3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.170 enrolled24 locationsNCT06679881
Recruiting

Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema

Hereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2
Istituti Clinici Scientifici Maugeri SpA30 enrolled1 locationNCT07448181
Recruiting

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

Hereditary Angioedema (HAE)
Takeda40 enrolled24 locationsNCT07251933
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting
Phase 1Phase 2

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Hereditary Angioedema (HAE)AngioedemaBradykinin-mediated Angioedema+1 more
Institute for Asthma and Allergy10 enrolled1 locationNCT07046806
Recruiting

HAE Burden and Crisis Management

Hereditary Angioedema (HAE)
University Hospital, Grenoble300 enrolled1 locationNCT06806618